Sarcoidosis is a systemic granulomatous disease of unknown etiology, in which the lungs and intrathoracic lymph nodes are predominant sites of involvement. Pulmonary hypertension is a known complication of sarcoidosis. Treatment of sarcoidosis-associated pulmonary hypertension has traditionally focused on the initiation of systemic corticosteroids, but has had inconsistent results. We present a patient with sarcoidosis-associated pulmonary hypertension who achieved substantial clinical improvement with the dual endothelin receptor antagonist bosentan.

Keywords:
Sarcoidosis, Pulmonary hypertension, Endothelin-1, Bosentan
1.
Preston IR, Klinger JR, Landzberg MJ, et al: Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001;120:866–872.
2.
Smith LJ, Lawrence JB, Katzenstein AA: Vascular sarcoidosis: a rare cause of pulmonary hypertension. Am J Med Sci 1983;285:38–44.
3.
Battesti JP, Georges R, Basset F, et al: Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978;33:76–84.
4.
Rodman DM, Lindenfeld J: Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest 1990;97:500–502.
5.
Gluskowski J, Hawrylkiewicz I, Zych D, et al: Effects of corticosteroid treatment on pulmonary hemodynamics in patients with sarcoidosis. Eur Respir J 1990;3:403–407.
6.
Jones K, Higenbottam T, Wallwork J: Pulmonary vasodilatation with prostacyclin in primary and secondary pulmonary hypertension. Chest 1989;96:784–789.
7.
Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin)with conventional therapy for primary pulmonary hypertension.N Engl J Med 1996;334:296–301.
8.
Simonneau G, Barst RJ, Galie N, et al: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800–804.
9.
Rubin LJ, Badesch DB, Barst RJ, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.
10.
American College of Chest Physicians Annual Meeting, Seattle, 2004.
11.
Badesch DB, Abman SH, Ahearn GS, et al: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S–62S.
12.
D’Alonzo GE, Barst RJ, Ayres SM, et al: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343–349.
13.
McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477–1482.
14.
McLaughlin VV, Sitbon O, Rubin LJ, et al: The effect of first-line bosentan on survival of patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2003;167:A442.
15.
Shorr AF, Darcy BD, Nathan SD: Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002;122:233–238.
16.
Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1998;332:411–415.
17.
Clozel M: Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med 2003;35:605–613.
18.
Giaid A, Yanagisawa M, Langleben D, et al: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732–1739.
19.
Reichenberger F, Schauer J, Kellner K, et al: Different expression of endothelin in the bronchoalveolar lavage fluid of patients with pulmonary diseases. Lung 2001;179:163–174.
20.
Letizia C, Danese A, Reale MG, et al: Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med 2001;43:257–261.
© 2006 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.